Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,059,464 | 811,276 | 536,666 | 242,677 | 887,867 |
| Depreciation Amortization | 145,183 | 106,462 | 69,835 | 34,063 | 129,936 |
| Income taxes - deferred | 131,204 | 99,675 | 6,427 | 3,948 | -24,194 |
| Accounts receivable | -68,722 | -82,586 | -74,889 | -45,240 | -28,280 |
| Accounts payable and accrued liabilities | -8,573 | -4,977 | -12,113 | -8,123 | 8,086 |
| Other Working Capital | -227,514 | -244,493 | -224,543 | -60,687 | -133,238 |
| Other Operating Activity | 150,763 | 140,688 | 122,322 | 71,324 | 88,824 |
| Operating Cash Flow | $1,181,805 | $826,045 | $423,705 | $237,962 | $929,001 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 1,987 | 483 | 890 | 416 | 554 |
| PPE Investments | -124,676 | -95,242 | -64,128 | -30,026 | -120,922 |
| Net Acquisitions | N/A | N/A | N/A | N/A | -76,694 |
| Purchase Sale Intangibles | -13,550 | -13,350 | N/A | N/A | -10,000 |
| Other Investing Activity | -13,550 | -13,350 | 0 | 0 | -10,000 |
| Investing Cash Flow | $-136,239 | $-108,109 | $-63,238 | $-29,610 | $-207,062 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 205,000 | 329,000 | 69,500 | N/A |
| Debt Issued | 250,000 | N/A | N/A | N/A | N/A |
| Debt Repayment | -428,385 | -103,386 | -103,386 | N/A | -75,000 |
| Common Stock Issued | 93,362 | N/A | 24,523 | 7,193 | 44,492 |
| Common Stock Repurchased | -1,224,203 | -986,369 | -746,089 | -407,014 | -847,565 |
| Other Financing Activity | 144,262 | 75,493 | 0 | 0 | 0 |
| Financing Cash Flow | $-1,164,964 | $-809,262 | $-495,952 | $-330,321 | $-878,073 |
| Exchange Rate Effect | 11,202 | 11,226 | 11,813 | -2,327 | -9,532 |
| Beginning Cash Position | 288,266 | 288,266 | 288,266 | 288,266 | 453,932 |
| End Cash Position | 180,070 | 208,166 | 164,594 | 163,970 | 288,266 |
| Net Cash Flow | $-108,196 | $-80,100 | $-123,672 | $-124,296 | $-165,666 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,181,805 | 826,045 | 423,705 | 237,962 | 929,001 |
| Capital Expenditure | -124,676 | -95,242 | -64,128 | -30,026 | -120,922 |
| Free Cash Flow | 1,057,129 | 730,803 | 359,577 | 207,936 | 808,079 |